『Power to the Patients』のカバーアート

Power to the Patients

Power to the Patients

著者： Brandon Li
無料で聴く

Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com315762 生物科学 科学
エピソード
  • The Gout Narrative Keeping Patients Sick and What Crystalys Therapeutics Is Doing Differently

    The Gout Narrative Keeping Patients Sick and What Crystalys Therapeutics Is Doing Differently
    2026/07/23
    Most people still think gout is a lifestyle condition caused primarily by diet. But this belief is a big reason patients have been underserved for decades. In this episode of Power to the Patients, Brandon Li sits down with James Mackay, CEO and co-founder of Crystalys Therapeutics, to explore what gout patients really need. They unpack what went wrong with Zurampic, why Dotinurad’s profile gives Crystalys Therapeutics a reason to come back to gout and how better trial design could finally move the field beyond old assumptions. For decades, gout has often been framed as a disease caused by lifestyle choices. This episode reframes the conversation entirely.
    続きを読む 一部表示
    36 分
  • Developing a treatment for Alzheimer's in the world of AI with Sacha Schermerhorn

    Developing a treatment for Alzheimer's in the world of AI with Sacha Schermerhorn
    2026/07/07
    Learn about clinical trial design for small molecule therapies using biomarkers in Alzheimer's research and AI in drug development. Brandon Li talks with Sacha Schermerhorn, Founder and CEO of Babylon Biosciences. They discuss why the industry needs to rethink disease pathology, how to recruit elite talent out of retirement, and the role of fine-tuned AI models in predicting clinical outcomes for patients.
    続きを読む 一部表示
    34 分
  • How Neuroplasticity Is Shaping the Next Generation of Psychiatric Medicines

    How Neuroplasticity Is Shaping the Next Generation of Psychiatric Medicines
    2026/05/13
    Dr. Aaron Koenig, Chief Medical Officer at Delix Therapeutics, sheds light on a new class of medicines designed to promote neuroplasticity without the hallucinogenic effects associated with psychedelics. On this episode of Power to the Patients, Koenig explains to host Brandon Li how neuroplasticogens could provide scalable treatments for depression and other serious brain disorders, why separating plasticity from psychedelic experiences matters for clinical development, and how emerging biomarkers such as qEEG may help measure brain changes in patients. The conversation spans scientific rationale, clinical challenges, and long term potential of plasticity-based therapeutics in psychiatry and neurology.
    続きを読む 一部表示
    34 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません